Cash, cash equivalents and marketable securities of $53.1 million as of December 31, 2024, are expected to support operations and development ...
6d
Stelios Papadopolous, Ph.D., a pioneering leader in biotech, appointed to Board of Directors; two industry veterans joined management team as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback